MN1 Antibody

What is the MN1 protein and why is it significant in research?

MN1 (meningioma disrupted in balanced translocation 1) is a DNA-binding protein that functions as a transcriptional coregulator interacting with the BAF complex. It was initially identified in meningiomas but has since been found to have significant roles in various malignancies. MN1 is particularly noteworthy as a negative prognostic factor in patients with acute myeloid leukemia (AML) with normal cytogenetics . Research has demonstrated that MN1 is a potent oncogene in hematopoiesis that both promotes proliferation/self-renewal and blocks differentiation, making it a valuable research target for understanding leukemogenesis and potential therapeutic approaches .

What are the validated applications for MN1 antibody in research settings?

MN1 antibody has been validated for multiple experimental applications including Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), and ELISA . The antibody has demonstrated reactivity with human samples, with cited reactivity extending to mouse samples as well . In immunohistochemistry applications, MN1 antibody has shown particular value as a diagnostic biomarker for MN1-altered tumors, with studies demonstrating 91.7% sensitivity and 95.5% specificity in diagnosing primitive CNS tumors with MN1 fusion .

What are the optimal storage conditions for maintaining MN1 antibody integrity?

For optimal performance, MN1 antibody should be stored at -20°C, where it remains stable for one year after shipment. The antibody is typically supplied in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Importantly, aliquoting is unnecessary for -20°C storage, which simplifies laboratory handling protocols. For smaller sizes (20μl), the preparation contains 0.1% BSA as a stabilizer . These storage conditions help maintain antibody performance across the recommended applications.

What are the recommended dilution ratios for different MN1 antibody applications?

Based on validated research protocols, the following dilution ranges are recommended for optimal results when using MN1 antibody:

It is strongly recommended to titrate the antibody in each testing system to obtain optimal results, as optimal dilutions may be sample-dependent . For published research applications like the diagnostic study of MN1-altered tumors, a dilution of 1:150 has been effectively used for IHC applications on formalin-fixed paraffin-embedded tissue samples .

How should MN1 immunohistochemistry staining be performed and interpreted?

For MN1 immunohistochemistry, the recommended protocol involves applying the anti-MN1 antibody (polyclonal; rabbit) to 3-μm-thick sections of formalin-fixed paraffin-embedded tissue samples. Automation systems such as OMNIS-Automation have been successfully employed in research settings . For antigen retrieval, TE buffer pH 9.0 is suggested, with citrate buffer pH 6.0 as an alternative option .

For interpretation of results, a three-tier scoring system has been validated in research settings:

• Score 1: <10% of cells with low-intensity nuclear staining

• Score 2: >10% with low intensity

• Score 3: >90% of tumor cells with high intensity

Positive MN1 IHC typically presents as strong nuclear labeling that is homogeneously diffuse and intense, which simplifies interpretation in diagnostic applications .

What cell lines have been validated for positive MN1 expression in Western blot applications?

Western blot detection of MN1 has been positively validated in MCF-7 cells and U2OS cells . These cell lines serve as appropriate positive controls when establishing MN1 Western blot protocols in research laboratories. When performing Western blot, researchers should expect to observe the MN1 protein at approximately 136 kDa, which matches its calculated molecular weight based on its 1320 amino acid sequence .

How does MN1 expression correlate with ATRA resistance in AML, and what are the methodological approaches to study this relationship?

Research has established that MN1 overexpression significantly increases resistance to all-trans retinoic acid (ATRA)-induced differentiation and cell-cycle arrest in AML models. Experimental data demonstrates that MN1 overexpression can increase resistance to ATRA-induced differentiation by more than 3000-fold in vitro . This resistance mechanism appears to function through MN1's repression of RARα target genes that are normally upregulated during ATRA treatment, including p21, p27, and PU.1 .

Methodologically, researchers can assess ATRA resistance by:

• Measuring proliferation curves with and without ATRA exposure (0.1μM and 1μM concentrations)

• Analyzing changes in immunophenotype through flow cytometry (markers Gr-1, Mac-1, and c-kit)

• Quantifying expression levels of ATRA-responsive genes like p21, p27, and PU.1 via RT-PCR or Western blot

• Examining morphological changes indicative of myeloid differentiation

What is the value of MN1 immunohistochemistry as a diagnostic biomarker for CNS tumors?

MN1 immunohistochemistry has emerged as a valuable diagnostic biomarker for CNS tumors, particularly those with MN1 alterations. Research evaluating MN1 IHC on 632 well-annotated tumor samples across 56 different histomolecular types/subtypes found that MN1 IHC demonstrates a sensitivity of 91.7% and specificity of 95.5% in diagnosing primitive CNS tumors with MN1 fusion .

The staining pattern is characterized by homogeneously diffuse and intense nuclear labeling, which simplifies interpretation in the diagnostic setting. This makes MN1 IHC particularly valuable as a quick and inexpensive screening tool to identify potential tumors with MN1 fusion, including astroblastomas (AB-MN1) and other tumor types .

Methodologically, researchers and diagnosticians can implement MN1 IHC with confidence that positive results strongly correlate with molecular findings from more time-consuming and expensive methods like DNA methylation profiling and RNA sequencing analyses.

How can MN1 expression be used as a predictive biomarker for treatment response in AML?

MN1 expression levels can serve as a predictive biomarker to guide treatment decisions in AML, particularly regarding ATRA therapy. Unlike prognostic markers that simply describe patient outcomes, MN1 expression functions as a predictive marker that can guide therapeutic choices .

• Stratification: Clinical trials investigating ATRA in non-APL AML should stratify patients based on MN1 expression levels

• Patient selection: MN1 expression analysis can identify patients likely to benefit from ATRA treatment

• Treatment guidance: Patients with high MN1 expression can be spared from ATRA treatment with its potential adverse effects

• Methodology validation: Results should be validated in independent patient cohorts

This approach aligns with the growing trend of using predictive biomarkers to personalize cancer treatment, similar to established practices in breast and lung cancers.

What are the methodological approaches to study MN1's mechanism of action in blocking cellular differentiation?

Advanced research into MN1's mechanism of action has revealed that it blocks differentiation through transcriptional repression. This understanding emerged from experiments where fusion of a transcriptional activator (VP16) to MN1 released the differentiation block without affecting MN1's ability to immortalize bone marrow cells .

Methodological approaches to investigate this mechanism include:

• Transcriptional fusion studies: Creating MN1-VP16 fusion constructs to test whether activation vs. repression affects differentiation capacity

• Gene expression analysis: Examining expression levels of differentiation-associated genes (p21, p27, PU.1) in MN1-overexpressing cells compared to controls

• Response to differentiation agents: Measuring the fold change in IC50 of differentiation-inducing agents (like ATRA) between MN1-expressing and control cells

• Immunophenotyping: Analyzing changes in surface markers (Gr-1, Mac-1, c-kit) that indicate differentiation state

These approaches have revealed that MN1 likely represses RARα target genes, either by directly binding to their regulatory sequences or by interacting with RARα itself, thus preventing differentiation in a mechanism resembling that of oncogenic RARα fusion proteins in acute promyelocytic leukemia .

How should researchers design experiments to distinguish between MN1's dual roles in promoting self-renewal and blocking differentiation?

MN1 has been identified as a unique oncogene in hematopoiesis that both promotes proliferation/self-renewal and blocks differentiation . Designing experiments to dissect these dual functions requires sophisticated methodological approaches:

• Domain-specific mutations: Creating constructs with mutations in specific functional domains of MN1 to identify regions responsible for each function

• Rescue experiments: Testing whether fusion constructs (like MN1-VP16) that restore differentiation still maintain proliferation/self-renewal functions

• Temporal regulation: Using inducible expression systems to determine whether MN1's effects on self-renewal and differentiation occur simultaneously or sequentially

• Epistasis studies: Examining whether enforced expression of differentiation-promoting factors can overcome MN1's differentiation block without affecting self-renewal

• Cell-specific contexts: Testing MN1's functions in different hematopoietic cell populations at various differentiation stages

Understanding this dual functionality is critical for developing potential therapeutic strategies that might selectively target one function while sparing the other, potentially reducing side effects.

What are the technical considerations when performing MN1 knockout/knockdown validation experiments?

When designing MN1 knockout or knockdown experiments for validation studies, several technical considerations must be addressed:

• Selection of knockdown approach: Published research has utilized both RNA interference and genetic knockout approaches for MN1 functional studies

• Validation of knockdown efficiency: Western blot using validated MN1 antibody should be performed to confirm reduction in protein expression, with appropriate loading controls

• Phenotypic analysis: Comprehensive assessment should include:

  • Proliferation assays

  • Differentiation markers

  • Colony formation capacity

  • Response to differentiation agents like ATRA

  • Gene expression analysis of MN1 target genes

• Control selection: Appropriate controls should include both wild-type cells and those expressing non-targeting control constructs

• Rescue experiments: To confirm specificity, researchers should attempt to rescue phenotypes by re-expressing MN1 constructs resistant to the knockdown strategy

Published research has demonstrated that MN1 knockdown studies can successfully validate its role in leukemogenesis and ATRA resistance, providing important insights into mechanism of action .

What are common challenges in MN1 immunohistochemistry and how can they be addressed?

When performing MN1 immunohistochemistry, researchers may encounter several technical challenges. Here are methodological solutions to address them:

• Antigen retrieval optimization: If initial staining is weak or inconsistent, researchers should test both recommended retrieval methods:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

• Background staining: If high background occurs, researchers should:

  • Titrate the antibody within the recommended range (1:20-1:200)

  • Increase washing steps duration and frequency

  • Consider using different blocking reagents

• Interpretation consistency: For diagnostic applications, implement the validated three-tier scoring system:

  • Score 1: <10% of cells with low-intensity nuclear staining

  • Score 2: >10% with low intensity

  • Score 3: >90% of tumor cells with high intensity

• Validation approach: Researchers should include known positive controls (such as confirmed MN1-fusion positive tumors) and negative controls (primary antibody omission) in each staining run to ensure reliability .

How can researchers evaluate the specificity of MN1 antibody in their experimental systems?

Ensuring antibody specificity is critical for generating reliable research data. For MN1 antibody, several methodological approaches can be employed to evaluate specificity:

• Positive and negative control tissues/cells:

  • Use validated positive controls: MCF-7 cells, U2OS cells, human breast cancer tissue, or human skeletal muscle tissue

  • Include negative controls: tissues known not to express MN1 or those with MN1 knockdown/knockout

• Peptide competition assay: Pre-incubate the antibody with excess MN1 immunogen (fusion protein Ag20344) to confirm signal elimination in positive samples

• Molecular validation: For diagnostic applications in tumors, confirm MN1 IHC results with orthogonal methods:

  • DNA methylation profiling

  • RNA sequencing to detect MN1 fusions

• Knockdown validation: Generate MN1 knockdown in positive cell lines and confirm signal reduction by Western blot and immunostaining

Implementing these validation approaches will ensure that experimental findings attributed to MN1 are specific and reproducible.